March 13th 2025
Immunotherapy pioneer Mark Frohlich, MD, CEO of Indapta Therapeutics, discusses the promise of harnessing natural killer cells to reshape treatment for cancer and autoimmune disease.
What Does the Future of Work Look Like for America’s Biopharma Sales Force?
June 29th 2021Harvard Business School Professor Joseph B. Fuller talks about the future prospects for pharma sales forces as they face more restrictions on accessing their target physicians and looming concerns of automation.
Career Insights: Astellas — Innovation and Value
October 7th 2020In this installment of the Harvard Business School Healthcare Alumni Association (HBSHAA) Q&A series, Percival Barretto-Ko, President of Astellas Pharma, US, speaks to Michael Wong about why value and innovation are the top two focus areas to add to resumes in 2020.